[go: up one dir, main page]

BR0308780A - Composto, processo para a preparação e uso do mesmo, método para o tratamento de um sujeito humano ou animal que sofre de, ou que é suscetìvel a, uma condição inflamatória, e, composição farmacêutica - Google Patents

Composto, processo para a preparação e uso do mesmo, método para o tratamento de um sujeito humano ou animal que sofre de, ou que é suscetìvel a, uma condição inflamatória, e, composição farmacêutica

Info

Publication number
BR0308780A
BR0308780A BR0308780-8A BR0308780A BR0308780A BR 0308780 A BR0308780 A BR 0308780A BR 0308780 A BR0308780 A BR 0308780A BR 0308780 A BR0308780 A BR 0308780A
Authority
BR
Brazil
Prior art keywords
human
compound
preparation
animal subject
inflammatory condition
Prior art date
Application number
BR0308780-8A
Other languages
English (en)
Inventor
Rachael Ancliff
Caroline Mary Cook
Colin David Eldred
Paul Martin Gore
Lee Andrew Harrison
Martin Alistair Hayes
Simon Teanby Hodgson
Duncan Bruce Judd
Suzanne Elaine Keeling
Xiao Qing Lewell
Gail Mills
Graeme Michael Robertson
Stephen Swanson
Andrew John Walker
Mark Wilkinson
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0207434A external-priority patent/GB0207434D0/en
Priority claimed from GB0301608A external-priority patent/GB0301608D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of BR0308780A publication Critical patent/BR0308780A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

"COMPOSTO, PROCESSO PAPA A PREPARAçãO E USO DO MESMO, MéTODO PARA O TRATAMENTO DE UM SUJEITO HUMANO OU ANIMAL QUE SOFRE DE, OU QUE E SUSCETìVEL A, UMA CONDIçãO INFLAMATóRIA, E, COMPOSIçãO FARMACêUTICA". Compostos de fórmula (I) em que: R1 representa heteroarila substituído ou não substituído; Y representa -(CRnaRnb)n-: Rna e Rnb são, cada um, independentemente hidrogênio ou alquila C~ 1-6~; n é um número inteiro de 0 a 5; R2 representa arila não substituído ou substituído ou heteroarila não substituído ou substituído; R3 e R4 cada um representa independentemente hidrogênio ou alquila C~ 1-6~; R7 representa hidrogênio ou alquila C~ 1-6~; R8 representa hidrogênio ou alquila C~ 1-6~; e seus sais e solvatos; são antagonistas de CCR3 e, portanto, são indicados como sendo úteis na terapia.
BR0308780-8A 2002-03-28 2003-03-27 Composto, processo para a preparação e uso do mesmo, método para o tratamento de um sujeito humano ou animal que sofre de, ou que é suscetìvel a, uma condição inflamatória, e, composição farmacêutica BR0308780A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0207434A GB0207434D0 (en) 2002-03-28 2002-03-28 Novel compounds
GB0301608A GB0301608D0 (en) 2003-01-24 2003-01-24 Novel compounds
PCT/EP2003/003335 WO2003082861A2 (en) 2002-03-28 2003-03-27 Morpholinyl-urea derivatives for use of the treatment of inflammatory diseases

Publications (1)

Publication Number Publication Date
BR0308780A true BR0308780A (pt) 2004-12-28

Family

ID=28676494

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0308780-8A BR0308780A (pt) 2002-03-28 2003-03-27 Composto, processo para a preparação e uso do mesmo, método para o tratamento de um sujeito humano ou animal que sofre de, ou que é suscetìvel a, uma condição inflamatória, e, composição farmacêutica

Country Status (23)

Country Link
US (1) US7622464B2 (pt)
EP (1) EP1487828B1 (pt)
JP (1) JP4465195B2 (pt)
KR (1) KR20040093488A (pt)
CN (1) CN1656092A (pt)
AR (1) AR040403A1 (pt)
AT (1) ATE413399T1 (pt)
AU (1) AU2003226757A1 (pt)
BR (1) BR0308780A (pt)
CA (1) CA2480106A1 (pt)
CY (1) CY1108652T1 (pt)
DE (1) DE60324535D1 (pt)
DK (1) DK1487828T3 (pt)
ES (1) ES2315519T3 (pt)
IL (1) IL164047A0 (pt)
IS (1) IS7444A (pt)
MX (1) MXPA04009459A (pt)
NO (1) NO20044448L (pt)
PT (1) PT1487828E (pt)
RU (1) RU2004127928A (pt)
SI (1) SI1487828T1 (pt)
TW (1) TW200400035A (pt)
WO (1) WO2003082861A2 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2387909T3 (es) 2003-01-14 2012-10-03 Cytokinetics, Inc. Compuestos, composiciones y procedimientos de tratamiento de la insuficiencia cardiaca
CA2520763A1 (en) 2003-04-03 2004-10-21 The Regents Of The University Of California Improved inhibitors for the soluble epoxide hydrolase
EP1765311A4 (en) 2004-03-16 2009-04-29 Univ California REDUCTION OF NEPHROPATHY WITH INHIBITORS OF SOLUBLE EPOXY HYDROLASE AND EPOXYEICOSANOIDS
MY144470A (en) 2004-06-17 2011-09-30 Cytokinetics Inc Compounds, compositions and methods
RU2006144821A (ru) 2004-07-08 2008-08-20 Ново Нордиск А/С (DK) Пролонгирующие метки полипептидов, содержащие тетразольную группировку
US7176222B2 (en) 2004-07-27 2007-02-13 Cytokinetics, Inc. Syntheses of ureas
US7935700B2 (en) 2004-09-08 2011-05-03 Mitsubishi Tanabe Pharma Corporation Morpholine compound
NZ554555A (en) 2004-10-20 2011-09-30 Univ California Cyclohexyl-urea derivatives as improved inhibitors for the soluble epoxide hydrolase
US7538223B2 (en) 2005-08-04 2009-05-26 Cytokinetics, Inc. Compounds, compositions and methods
TW200808321A (en) 2005-12-15 2008-02-16 Cytokinetics Inc Certain chemical entities, compositions and methods
US7825120B2 (en) 2005-12-15 2010-11-02 Cytokinetics, Inc. Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas
EP1959962A2 (en) 2005-12-16 2008-08-27 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
JP5178526B2 (ja) 2005-12-19 2013-04-10 サイトキネティクス・インコーポレーテッド 化合物、組成物および方法
TW200808723A (en) 2006-03-13 2008-02-16 Univ California Conformationally restricted urea inhibitors of soluble epoxide hydrolase
EP2182809B1 (en) * 2007-08-27 2018-01-17 Dart Neuroscience (Cayman) Ltd Therapeutic isoxazole compounds
WO2012054093A2 (en) 2010-01-29 2012-04-26 The Regents Of The University Of California Acyl piperidine inhibitors of soluble epoxide hydrolase
RU2512293C1 (ru) * 2012-12-13 2014-04-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Ярославский государственный технический университет" Способ получения этил 1,2,4-оксадиазол-5-карбоксилатов
CN107362362B (zh) * 2017-07-20 2019-01-01 复旦大学 Sirt1抑制剂在预防和治疗放射引起的肠道疾病中的应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4851526A (en) 1987-09-04 1989-07-25 Schering A.G. 1-(4-Substituted phenyl)-1H-imidazoles compounds
JP3087763B2 (ja) * 1990-11-30 2000-09-11 三井化学株式会社 新規な複素環式化合物およびそれを含有する医薬組成物
US5219856A (en) 1992-04-06 1993-06-15 E. I. Du Pont De Nemours And Company Angiotensin-II receptor blocking, heterocycle substituted imidazoles
US5807857A (en) 1994-05-19 1998-09-15 Merck Sharp & Dohme Ltd. Piperazine, piperidine and tetrahydropyridine derivative of indol-3-alkyl as 5-HT1D-α agonists
EP0772611A1 (de) 1994-07-20 1997-05-14 Byk Gulden Lomberg Chemische Fabrik GmbH Piperazinothiopyridine zur bekämpfung von helicobacter-bakterien
US5654316A (en) 1995-06-06 1997-08-05 Schering Corporation Piperidine derivatives as neurokinin antagonists
AU2980797A (en) 1996-06-11 1998-01-07 Yoshitomi Pharmaceutical Industries, Ltd. Fused heterocyclic compounds and medicinal uses thereof
US5919776A (en) * 1996-12-20 1999-07-06 Merck & Co., Inc. Substituted aminoquinolines as modulators of chemokine receptor activity
US6207665B1 (en) 1997-06-12 2001-03-27 Schering Aktiengesellschaft Piperazine derivatives and their use as anti-inflammatory agents
IT1293807B1 (it) 1997-08-01 1999-03-10 Recordati Chem Pharm Derivati 1- (n-fenilaminoalchil) piperazinici sostituiti alla posizione 2 dell'anello fenilico
WO1999021848A2 (en) 1997-10-27 1999-05-06 Neurogen Corporation Novel 1-(n'-(arylalkylaminoalkyl))aminoisoindoles; a new class of dopamine receptor subtype specific ligands
US6031097A (en) 1997-10-27 2000-02-29 Neurogen Corporation 1-(N-(arylalkylaminoalkyl) aminoisoquinolines; a new class of dopamine receptor subtype specific ligands
AU6280199A (en) 1998-09-30 2000-04-17 Neurogen Corporation 2-piperazino alkylamino benzoazole derivatives: dopamine receptor subtype specific ligands
IL155092A0 (en) * 2000-09-29 2003-10-31 Glaxo Group Ltd Compounds useful in the treatment of inflammatory diseases
CN1678594A (zh) 2000-09-29 2005-10-05 葛兰素集团有限公司 用于治疗炎性疾病的吗啉－乙酰胺衍生物

Also Published As

Publication number Publication date
IL164047A0 (en) 2005-12-18
AU2003226757A1 (en) 2003-10-13
JP2005526815A (ja) 2005-09-08
MXPA04009459A (es) 2005-01-25
CN1656092A (zh) 2005-08-17
IS7444A (is) 2004-09-13
ES2315519T3 (es) 2009-04-01
TW200400035A (en) 2004-01-01
DK1487828T3 (da) 2009-02-02
NO20044448L (no) 2004-10-26
PT1487828E (pt) 2009-01-06
US7622464B2 (en) 2009-11-24
DE60324535D1 (de) 2008-12-18
EP1487828A2 (en) 2004-12-22
CA2480106A1 (en) 2003-10-09
AR040403A1 (es) 2005-04-06
RU2004127928A (ru) 2005-06-27
WO2003082861A2 (en) 2003-10-09
WO2003082861A3 (en) 2004-03-11
CY1108652T1 (el) 2014-08-13
SI1487828T1 (sl) 2009-04-30
EP1487828B1 (en) 2008-11-05
US20060063765A1 (en) 2006-03-23
KR20040093488A (ko) 2004-11-05
JP4465195B2 (ja) 2010-05-19
ATE413399T1 (de) 2008-11-15

Similar Documents

Publication Publication Date Title
BR0308780A (pt) Composto, processo para a preparação e uso do mesmo, método para o tratamento de um sujeito humano ou animal que sofre de, ou que é suscetìvel a, uma condição inflamatória, e, composição farmacêutica
BR0313160A (pt) Composto, composição farmacêutica, métodos para tratar uma condição e um neoplasmo suscetìvel em um animal em um animal, processo para preparar um composto e uso de um composto
BR0307409A (pt) Compostos de hidrazida de ácido 2-furanocarboxìlico, composições farmacêuticas contendo os mesmos e uso dos mesmos para preparação de um agente preventivo ou terapêutico
BG66094B1 (bg) Азабициклени съединения, тяхното получаване и използване като лекарствени средста, по-специално като антибактериални средства
BR0209271A (pt) Composto, uso de um composto composição farmacêutica, formulação em aerossol farmacêutica, método para o tratamento de um paciente humano ou animal com uma condição inflamatória e/ou alérgica, e, processo para a preparação de um composto
BRPI0606817A2 (pt) derivados de piridazina e seu uso como agentes terapêuticos
NO20060972L (no) Pyridylderivater og deres anvendelse som terapeutiske midler
MX2007003508A (es) Diaril ureas ciclicas adecuadas como inhibidores de tirosina cinasa.
HUP0300846A2 (hu) Imidazopirimidin- és triazolopirimidin-származékok, eljárás előállításukra és ilyen vegyületeket tartalmazó gyógyszerkészítmények
AR032436A1 (es) Oxazolidinonas substituidas, procedimiento para su preparacion, medicamentos, el uso de las mismas para la fabricacion de medicamentos, y el metodo para impedir la coagulacion sanguinea in vitro
HUP0202623A2 (hu) MEK-gátló vegyületek alkalmazása gyógyászati készítmények előállítására
NO20060974L (no) Pyridazinderivater og deres anvendelse som terapeutiske midler
UY27368A1 (es) Nuevos compuestos
BR9908764A (pt) Composto e seus sais farmaceuticamente aceitáveis ou ésteres hidrolisáveis in vivo, uso destes, processo para prepará-los, e, composição farmacêutica
BR0317705A (pt) Composto, formulação farmacêutica, uso de um composto, método de tratamento de doenças ou condições, e, processo para a preparação de compostos
FR2903107B1 (fr) Derives d'imidazopyridine-2-carboxamides, leur preparation et leur application en therapeutique
UY27872A1 (es) Inhibidores de caspasa y usos de los mismos.
HUP0002272A2 (hu) Piperazinszármazékok, eljárás előállításukra, e vegyületeket tartalmazó gyógyászati készítmények és alkalmazásuk
BR0209518A (pt) Novos derivados arilheteroalquilamina
PE20070212A1 (es) Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen
NO20070837L (no) Pyrido-pyrido pyrimidinderivater, fremstilling derav samt terapeutisk anvendelse for behandling av cancer.
BR0011340A (pt) Composto, processo para preparar o composto, composição, uso de um composto, e, método de tratar doenças alérgicas incluindo a asma brÈnquica, rinite, conjuntivite, dematose e urticária
BRPI0514036A (pt) composto, sais farmaceuticamente aceitáveis do mesmo, diastereÈmeros, enanciÈmeros ou misturas do mesmo, uso de um composto, composição farmacêutica, método para a terapia de depressão em um animal de sangue quente, e, processo para preparar um composto
ATE268752T1 (de) Aralkyl-1,2-diaminen mit calcimimetischer wirkung und verfahren zu ihrer herstellung
SE0301701D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]